Two dementia medicines set for approval in Britain are first to improve patients’ lives directly – but condition must be diagnosed
People in Britain could benefit from a key medical breakthrough next year. They may be given access to the first drugs ever developed to slow the impact of Alzheimer’s disease.
The first of these medicines – lecanemab – was recently approved in the US and Japan, where treatments using it have already been launched. A second drug, donanemab, is expected to follow soon, and next year it is anticipated that the UK medical authorities will consider both of them for approval in Britain.
About Author
More Stories
Microsoft unveils chip it says could bring quantum computing within years
I keep fantasising about living in total solitude in a forest
Opening our eyes to the science of sleep, in 1971